Capital Investment Advisory Services LLC Has $217,000 Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Capital Investment Advisory Services LLC decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 8.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,096 shares of the company’s stock after selling 189 shares during the quarter. Capital Investment Advisory Services LLC’s holdings in Novo Nordisk A/S were worth $217,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Clarius Group LLC lifted its holdings in shares of Novo Nordisk A/S by 0.5% during the fourth quarter. Clarius Group LLC now owns 18,505 shares of the company’s stock worth $1,914,000 after buying an additional 93 shares in the last quarter. Tradewinds Capital Management LLC lifted its holdings in shares of Novo Nordisk A/S by 2.0% during the fourth quarter. Tradewinds Capital Management LLC now owns 4,955 shares of the company’s stock worth $513,000 after buying an additional 95 shares in the last quarter. Relyea Zuckerberg Hanson LLC lifted its holdings in shares of Novo Nordisk A/S by 3.2% during the fourth quarter. Relyea Zuckerberg Hanson LLC now owns 3,159 shares of the company’s stock worth $327,000 after buying an additional 99 shares in the last quarter. Fort Washington Investment Advisors Inc. OH lifted its holdings in shares of Novo Nordisk A/S by 3.5% during the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 2,960 shares of the company’s stock worth $306,000 after buying an additional 100 shares in the last quarter. Finally, Highlander Capital Management LLC lifted its holdings in shares of Novo Nordisk A/S by 0.4% during the fourth quarter. Highlander Capital Management LLC now owns 25,100 shares of the company’s stock worth $2,597,000 after buying an additional 100 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. UBS Group assumed coverage on Novo Nordisk A/S in a research report on Tuesday, January 16th. They issued a “neutral” rating on the stock. BMO Capital Markets assumed coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price target on the stock. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price target on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S has an average rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock opened at $126.20 on Thursday. Novo Nordisk A/S has a 12-month low of $75.56 and a 12-month high of $138.28. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19. The business’s 50-day moving average price is $126.72 and its two-hundred day moving average price is $111.64. The stock has a market cap of $566.33 billion, a PE ratio of 46.65, a P/E/G ratio of 2.15 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. The firm had revenue of $9.51 billion for the quarter, compared to analysts’ expectations of $9.14 billion. As a group, analysts expect that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were issued a dividend of $0.664 per share. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. This represents a dividend yield of 0.9%. The ex-dividend date was Friday, March 22nd. Novo Nordisk A/S’s payout ratio is 49.17%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.